Novel Technologies for Vaccine Development

Herausgegeben:Lukashevich, Igor S; Shirwan, Haval

• Gebundenes Buch

Produktbeschreibung

This book presents a detailed overview of the development of new viral vector-based vaccines before discussing two major applications: preventive vaccines for infectious diseases and therapeutic cancer vaccines. Viral vector-based vaccines hold a great potential for development into successful pharmaceutical products and several examples at the advanced pre-clinical or clinical stage are presented. Nevertheless, the most efforts were focused on novel and very innovative technologies for new generation of vector-based vaccines. Furthermore, specific topics such as delivery and adjuvant and protection strategies for cell-mediated-based vaccines are presented. Given its scope, the book is a "must read" for all those involved in vaccine development, both in academia and industrial vaccine development.

Produktdetails

• Verlag: Springer / Springer Vienna / Springer, Wien
• Artikelnr. des Verlages: 86210017, 978-3-7091-1817-7
• 2014
• Seitenzahl: 400
• Erscheinungstermin: 1. Dezember 2014
• Englisch
• Abmessung: 241mm x 160mm x 27mm
• Gewicht: 707g
• ISBN-13: 9783709118177
• ISBN-10: 3709118174
• Artikelnr.: 41099061

Inhaltsangabe

Reverse Genetics Approaches for Rational Design of Inactivated and Live-Attenuated Influenza Vaccines.- Viral-Vectored Vaccines to Control Pathogenic Filoviruses.- Alphavirus Replicon Vectors for Prophylactic Applications and Cancer Intervention.- Current Status and Future of Polio Vaccines and Vaccination.- Current Status of Hantavirus Vaccines Development.- Experimental DNA-Launched Live Attenuated Vaccines against Infections Caused by Flavi- and Alphaviruses.- Sugar-Based Immune Adjuvants for Use in Recombinant, Viral, Vector, DNA and Other Styles of Vaccines.- Adenovirus-based Vectors for the Development of Prophylactic and Therapeutic Vaccines.- Radiovirotherapy for the Treatment of Cancer.- TRICOM Poxviral-Based Vaccines for the Treatment of Cancer.- The Use of Oncolytic Herpesvirus for the Treatment of Cancer.- SA-4-1BBL; A Novel form of the 4-1BB Costimulatory Ligand as an Adjuvant Platform for the Development of Subunit Cancer Vaccines.